Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envarsus vs. IR Tacrolimus for Neurocognitive Side Effects in Elderly Kidney Transplant Patients
NCT03461445Phase 4Completed
- Sponsor
- University of California, Davis
- Start
- Apr 2018
- Primary completion
- Jul 2023
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus in neurotoxicity, sponsored by University of California, Davis. Primary endpoint: Change in Neurocognitive Side Effects at 6 weeks. Started Apr 2018; status: completed.
02
Drugs
tacrolimus
03
Conditions
neurotoxicity
Beyond the preview
Go deeper on NCT03461445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03461445.